Hsa-miR-29c-3p Regulates Biological Function of Colorectal Cancer by Targeting SPARC
Overview
Affiliations
Colorectal cancer (CRC) is the most common type of behavioral cancers, miRNAs play a critical role in cancer development and progression. In the present study, we downloaded the original data from Gene Expression Omnibus (GEO) and conduct data analysis. has-mir-29c-3p mimic, inhibitor, negative control or si-SPARC (secreted protein acidic, rich in cysteine) were transfected into HCT116 cells, respectively. Quantitative real time PCR (qRT-PCR) was used to measure has-mir-29c-3p and SPARC mRNA expressions, western blot was used to detect ACAA1 (acetyl-CoA acyltransferase 1), ACOX1 (acyl-CoA oxidase 1), COL1A1(collagen, type I, alpha-1), COL1A2 (collagen, type I, alpha-2), COL4A1 (collagen, type IV, alpha-1), COL5A2 (collagen, type V, alpha-2), COL12A1 (collagen, type XII, alpha-1), CPT2 (carnitine palmitoyltransferase 2), ETHE1 (persulfide dioxygenase), HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2), SPARC, SQRDL (sulfide quinone oxidoreductase), and TST (thiosulfate sulfurtransferase) protein expression. CCK-8 and wound healing assay were employed to verify cell proliferation and migration. The luciferase reporter assay data made sure the target correlation of has-mir-29c-3p and SPARC. Firstly, we found that the expression of has-mir-29c-3p was lower in CRC tissues than in their paired corresponding non-cancerous tissues and there was significant inversed correlation between has-mir-29c-3p and SPARC. Overexpression of has-mir-29c-3p reduced cell proliferation and migration. SPARC was identified as a direct target of has-mir-29c-3p, whose silencing reduced cell proliferation and migration. These data showed that has-mir-29c-3p regulates CRC cell functions through regulating SPARC expression. Taken together, has-mir-29c-3p may function as an oncogenic miRNA targeting SPARC, targeted modulation of has-mir-29c-3p expression may became a potential strategy for the treatment.
Pei X, Luo Y, Zeng H, Jamil M, Liu X, Jiang B Aging (Albany NY). 2024; 16(12):10615-10635.
PMID: 38913913 PMC: 11236316. DOI: 10.18632/aging.205965.
GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs.
Ji Q, Zhu H, Qin Y, Zhang R, Wang L, Zhang E Front Pharmacol. 2024; 15:1329636.
PMID: 38323081 PMC: 10844528. DOI: 10.3389/fphar.2024.1329636.
Botor M, Augusciak-Duma A, Lesiak M, Sieron L, Dziedzic-Kowalska A, Witecka J Pharmaceuticals (Basel). 2023; 16(10).
PMID: 37895885 PMC: 10609877. DOI: 10.3390/ph16101414.
Yadav S, Jauhari A, Singh N, Pandey A, Sarkar S, Pandey S Cell Mol Neurobiol. 2023; 43(7):3527-3553.
PMID: 37219663 PMC: 11410010. DOI: 10.1007/s10571-023-01362-4.
Liu Z, Zhao E, Li H, Lin D, Huang C, Zhou Y Front Genet. 2023; 14:1105368.
PMID: 37205121 PMC: 10187888. DOI: 10.3389/fgene.2023.1105368.